We aimed to estimate the potential number of patients eligible for treatment with drotrecogin alfa (activated) when applying different international criteria.
Severe sepsis is a common and increasing public health problem. recent epidemiological studies suggest the annual incidence of severe sepsis is between 0.8 and 3.0 cases per 1000 [1] [2] [3] , and the mortality rate is around 30-32% [3] [4] [5] [6] . In addition, the treatment of patients with severe sepsis is expensive. Angus estimated the average cost per episode of severe sepsis at uS$22,100 with treatment of non survivors costing more than that of survivors 1 . Subsequent to Angus' estimate, drotrecogin alfa (activated) has been licensed for the treatment of severe sepsis in the u.S.A., Australia, New Zealand, Europe and other countries. The average cost of a four-day course of drotrecogin alfa (activated) is uS$6800, potentially increasing the cost of treating severe sepsis by a further 30%. however, drotrecogin alfa (activated) has anticoagulant properties making it relatively or absolutely contraindicated in patients at risk of bleeding 4 , and this reduces the number of patients eligible for treatment. In addition, the use of drotrecogin alfa (activated) has been limited by licensing restrictions or recommendations in many jurisdictions. Thus the number of patients eligible for treatment with drotrecogin alfa (activated) may vary between countries and the potential costs and benefits to national healthcare systems are not known. An estimate of the true number of patients eligible for treatment is essential to assist clinicians, managers and healthcare-funders make informed judgements about the place of drotrecogin alfa (activated) in the treatment of patients with severe sepsis and its potential impact on health care budgets.
The Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG) previously reported the results of an inception cohort study of severe sepsis in adult Intensive Care units in Australia and New Zealand 3 . From these data we have estimated the number of patients with absolute and relative contraindications to treatment with drotrecogin alfa (activated) and the number of patients fulfilling the licensing indications in Europe, the u.S.A., Australia and New Zealand. We have estimated the number of adults eligible for treatment with drotrecogin alfa (activated) in these four jurisdictions, the potential cost of such treatment and the potential benefit in terms of lives saved.
mEThoDS
The data used for this study came from the ANZICS CTG study of sepsis epidemiology and the detailed study methodology has been published previously 3 . In summary, all admissions to 23 participating ICus in 21 hospitals during the three months from 1 may 1999 to 31 July 1999 were screened daily for the presence of severe sepsis using standard diagnostic criteria 7 . organ dysfunction criteria for the diagnosis of severe sepsis were derived from the criteria used in the ProWESS study 4 . The Sequential organ Failure Assessment (SoFA) score 8 was used to assess organ function at baseline and while the patients were in the ICu. Demographic data and admission Acute Physiology and Chronic health Evaluation II (APAChE II) scores 9 were collected.
The study identified 752 episodes of severe sepsis in 691 patients. Each patient's initial episode was assessed for contraindications to treatment with drotrecogin alfa and for compliance with the licence conditions or recommendations for drotrecogin alfa (activated) in Australia, New Zealand, Europe and the u.S.A. The licence conditions applied were as follows: New Zealand and u.S.A.-an APAChE II score of 25 or greater 10, 11 ; Europe-dysfunction of two or more organs 12 ; Australia-dysfunction of two or more organs or an APAChE II score of 25 or greater 13 .
We considered conditions listed in the exclusion criteria of the ProWESS study as associated with an increased risk of bleeding to be either absolute or relative contraindications to treatment with drotrecogin alfa (activated): these are listed in Table  1 . Presence of these conditions in individual patients was determined by examination of the admission diagnoses listed in the original study database. using the original ICu admission diagnosis, patients were then divided into three groups on the basis of their eligibility for treatment with drotrecogin alfa (activated); those with an absolute contraindication, those with a relative contraindication and those with no contraindication. In addition to this, patients with a SoFA coagulation score of 4 (representing the closest value to platelets <30000) or a SoFA liver score of 4 (representing hepatic failure) were recorded as relative contraindications. Drotrecogin alfa (activated) was considered relatively contraindicated in patients admitted to the ICu immediately following myocardial infarction on the assumption they would have received either thrombolysis or anti-platelet therapy for acute coronary artery stenting.
In order to determine the number of patients eligible for treatment under the terms of the Australian, European, New Zealand and u.S. licences or recommendations, we identified patients with an APAChE II score of 25 and/or two or more organ failures. The presence of organ dysfunction was established using the individual organ SoFA score on the day of onset of severe sepsis which most closely reflected the organ dysfunction criteria used in the ProWESS study. A comparison of the SoFA-derived organ dysfunction criteria and the criteria used in the ProWESS study is given in Table 2 .
To check database quality, 5% of the records in the database were manually cross-checked with the original study case report forms.
Estimates for the treatment effects of drotrecogin alfa (activated) in subgroups of patients stratified by APAChE II score and multiple organ dysfunction were obtained from peer-reviewed publications [14] [15] [16] .
rESulTS

Data quality
There were no errors detected in data entry from the original case report forms to the database used in this study.
Presence of absolute or relative contraindications
of 691 patients diagnosed with severe sepsis, 74 (10.7%, 95% confidence interval 8.4%-13.0%) had an absolute contraindication to treatment with drotrecogin alfa (activated) ( Table 3 ). The most common absolute contraindications were trauma (25 of 74 patients-33.8%), intracranial haemorrhage (16 of 74 patients-21.6%), burns (13 of 74 patients-17.6%), vascular surgery (10 of 74 patients-13.5%) and gastrointestinal bleeding (7 of 74 patients-9.5%). Sixty-four patients (9.3%, 95% confidence interval 7.1-11.4%) had a relative contraindication to treatment with drotrecogin alfa (activated). (Table 3) The most common relative contra-indications were admission following acute myocardial infarction (29 of 64 patients-45.3%) and hepatic failure (8 of 64 patients-12.5%). 553 of 691 patients (80.0%, 77.0-83.0%) had no absolute or relative contraindication to treatment with drotrecogin alfa (activated).
Eligibility of patients with a relative contraindication
of 64 patients with a relative contraindication to treatment with drotrecogin alfa (activated), 33 (51.6%) had an APAChE II score of 25 or greater, 55 (85.9%) had dysfunction of two or more organs, and 56 patients (87.5%) had either dysfunction of two or more organs or an APAChE II score of 25 or greater ( Figure 1 ).
Eligibility of patients with no relative contraindication
of 553 patients with no relative contraindication to treatment with drotrecogin alfa (activated), 175 (31.6%) had an APAChE II >25, 372 (67.3%) had dysfunction of two or more organs, and 413 patients (74.7%) had either dysfunction of two or more organs or an APAChE II score of 25 or greater ( Figure 1 ).
Eligibility of patients with no absolute contraindication
of 617 patients with no absolute contraindication to treatment with drotrecogin alfa (activated), 208 (33.7%) had an APAChE II score of 25 or greater, ≥1-mean arterial pressure less than 70 mmhg Either : or the use of inotropes or vasopressors • Arterial systolic blood pressure ≤90 mmhg or mean arterial pressure ≤70 mmhg for at least 1h despite adequatefluid resuscitation or adequate intravascular volume status • The need for vasopressors to maintain systolic blood pressure a ≥90 mmhg or mean arterial pressure ≥70 mmhg renal ≥2-creatinine concentration greater than urine output <0.5 ml/kg per hour for 1h, despite adequate 0.17 mmol/l or urine output less than luid resuscitation 500 ml per day 451 (73.1%) had dysfunction of two or more organs, and 469 patients (76.0%) had either dysfunction of two or more organs or an APAChE II score of 25 or greater (Figure 1 ).
Eligibility of patients with no absolute contraindication per ICU admission episode
In 5878 ICu admission episodes, 208 patients (3.5%, 95% confidence interval 3.1-4.0%) had no absolute contraindication to treatment with drotrecogin alfa (activated) and an APAChE II score of 25 or greater, 451 (7.7%, 7.0-8.4%) had no absolute contraindication to treatment with drotrecogin alfa (activated) and dysfunction of two or more organs, and 469 patients (8.0%, 95% confidence interval 7.3-8.7%) had either dysfunction of two or more organs or an APAChE II score of 25 or greater (Figure 1 ). (Table 4) Applying the criteria or recommendations for eligibility for treatment in the u.S.A. and New Zealand (APAChE II score 25 or greater), Europe (including the united Kingdom) (two or more organ failures) and Australia (either an APAChE II score 25 or greater or two or more organ failures) to the 553 patients with no absolute contraindication to treatment, the maximum number of patients eligible for treatment would be 208/553 (37.6%) in the u.S.A. and New Zealand, 451/553 (81.6%) in Europe and 469/553 (84.8%) in Australia.
Eligibility using different geographical criteria
DISCuSSIoN
In this post hoc analysis of data from the ANZICS CTG sepsis study we have explored the number of patients eligible for treatment with drotrecogin alfa (activated) based on the absence of an absolute contraindication and on the licensed indications or recommendations in Australia, New Zealand, Europe and the u.S.A. our data, drawn from a study of 23 ICus in 21 hospitals in Australia and New Zealand, suggest that relatively few patients with severe sepsis have an absolute contraindication to treatment with drotrecogin alfa (activated). our data also suggest that of the criteria used to assess patients for treatment, the use of organ dysfunction criteria results in substantially more patients being eligible than use of the patient's admission APAChE II score.
In the ProWESS study, the overall reduction in mortality in patients treated with drotrecogin alfa (activated) was 6.1% 4 but the effect was limited to those patients with an increased risk of death as indicated by either an APAChE II score of 25 or greater 14 or two or more organ failures 15 . As a result, these indicators of higher risk of death have been used to restrict the licensed indications or recommendations for drotrecogin alfa (activated) in different jurisdictions. In the ProWESS study the absolute reduction in 28-day all cause mortality for patients with an APAChE II score of 25 or greater can be calculated as 11.5% 14, 17 , for patients with dysfunction of two or more organs the absolute reduction in 28-day all cause mortality was 7.4% 15 .
Extrapolating these figures to clinical practice would suggest that treatment of nine patients with an APAChE II score of 25 or greater will prevent one death whereas 13.5 patients with two or more organ dysfunctions would have to be treated to prevent one death. The number needed to treat is 33.3% less using an APAChE II score of 25 or greater as the criterion for treatment. use of the APAChE II score criterion appears attractive because it will select a population of patients who derive the greatest benefit from treatment with drotrecogin alfa (activated). however, although the number needed to treat to save one life is reduced by 33.3% using this criterion, our data suggest the number of patients eligible for treatment may be reduced by almost 54% and so use of the APAChE II score criterion may reduce the overall benefit of treatment. one issue limiting the use of drotrecogin alfa (activated) may be its cost. Drotrecogin alfa (activated) costs approximately uS$6800 per therapeutic course and its cost effectiveness has been assessed using the data from the ProWESS Study 16, 17 . using the ProWESS study data, Angus estimated that treating all patients with severe sepsis would cost uS$48,800 per quality adjusted life year (QAlY) obtained, but only uS$27,400 per QAlY if only those patients with an APAChE II score of 25 or greater were treated 16 . manns estimated the cost per QAlY at uS$27,936 for all patients and uS$24,484 for those with an APAChE II score of 25 or greater 17 . We are not aware of any calculation of the cost effectiveness of drotrecogin alfa (activated) in patients selected on the basis of multiple organ dysfunction but our data would suggest the cost effectiveness would lie between that for the whole population of patients with severe sepsis and those with an APAChE II score of 25 or greater. In health economics terms, selection of patients using either the APAChE II score or multiple organ dysfunction would be considered cost-effective 16 . For those with responsibility for ICu budgets, the drug acquisition cost of drotrecogin alfa (activated), may be of more interest than the cost per life saved or QAlY obtained. our data would suggest that if the APAChE II score is used 3.5 patients will be eligible for treatment with drotrecogin alfa (activated) for each 100 ICu admissions: if multiple organ dysfunction is used as the selection criterion then 7.7 patients would be eligible per 100 ICu admissions. In Australia where the government funded Pharmaceutical Benefits Scheme will pay for drotrecogin alfa (activated) if the patient has either an APAChE II score of 25 or greater or multiple organ dysfunction, our data suggest 8.0 patients will be eligible per 100 ICu admissions. These figures should allow ICu budget-holders to consider the potential cost of drotrecogin alfa (activated) if all eligible patients are treated.
our study has a number of limitations which must be recognised. The original inception cohort study was conducted in a selection of Australian and New Zealand hospitals comprising predominantly tertiary referral units and so the applicability of the data to other units and countries can not be assumed. The APAChE II score collected in our study was based on data collected during the patients first 24 hours in intensive care whereas the APAChE II score in the ProWESS study was collected using data in the 24 hours before the patient was randomized to study treatment; this may have included data both before and after the first 24 hours in intensive care and the two scores may not be completely comparable. We determined the number of patients with two or more organ failures using the SoFA score and these definitions are not exactly comparable with the definitions used in the ProWESS study. In addition we have estimated the number of patients who are potentially eligible for treatment with drotrecogin alfa (activated) and this does not equate to the number of patients who should receive treatment. Patients may develop severe sepsis as the terminal event in the course of another disease process and in such circumstances a palliative approach may be more appropriate.
The major strength of our study is that although this is a post hoc analysis, the data on which it is based was collected prospectively, it was collected during the conduct of the ProWESS study and the data definitions used were based on those of the ProWESS study 3 . The quality of the data in the original study compares very favourably with that of other similar studies 3 .
In conclusion, our data suggest that relatively few patients with severe sepsis have an absolute contraindication to treatment with drotrecogin alfa (activated). Compared to selection based on the presence of organ dysfunction, patient selection based on the APAChE II score results in fewer eligible patients. using the most liberal selection criterion, eight patients may be eligible for treatment with drotrecogin alfa (activated) for every 100 ICu admissions.
